CooperVision (NYSE:COO) announced today that its DreamLite night contact lenses received CE mark approval for children with myopia.
San Ramon, Calif.-based CooperVision designed its DreamLite night lenses to slow the progression of myopia in children with a refraction of -0.75 D to -5.00 D and a cylindrical refraction with a maximum of -2.50 D, according to a news release.
The company touted a two-year study of DreamLite that demonstrated reduced axial length growth by 63% among high myopes in DreamLite night lenses when compared to the single-vision spectacle lens control group.
DreamLite night lenses are now available across Europe with the CE mark and are also for sale in the Middle East and in China, CooperVision said.
“Myopia’s increasing frequency and prevalence is one of the most discussed issues in eye health. But conversation without action will not change the lives of the hundreds of millions of children affected by the issue. That sentiment is echoed by the World Council of Optometry, which recently passed a resolution advising optometrists to incorporate a standard of care for myopia management within their practices,” CooperVision president of specialty eyecare Dr. Juan Carlos Aragón said in the release. “Our commitments to innovations such as DreamLite night lenses, providing broader access to optical interventions with scientifically demonstrated outcomes, and investing in widespread education for eye care professionals and parents are examples why CooperVision continues to lead the myopia management category.
“The latest CE Mark will help ECPs communicate with even more confidence about DreamLite lenses’ ability to slow the progression of myopia.”